The 41BB-agonist potentiates the therapeutic efficacy of a combined irreversible electroporation ablation treatment of lung cancer by promoting unexpected CD8+CD103+ cDC1 and tissue-resident memory T cell responses
Fang Chen(University of Saskatchewan), Jim Xiang(University of Saskatchewan), Michelle Yu(University of Saskatchewan), Mike Moser(Roswell Park Comprehensive Cancer Center), Scot C. Leary(University of Saskatchewan), Zhaojia Wu(University of Saskatchewan), Yiling Bai(University of Saskatchewan), Junqiong Huang(Zunyi Medical University), Bing Zhang(Xi'an Jiaotong University), Wenjun Zhang(Shanghai Jiao Tong University), Haitao Ma(Soochow University), Yu F(Shanghai Maritime University), Gary Groot(Royal University Hospital), Nicolas Baniak(University of Saskatchewan), Shahid Ahmed(Emory University)
Cited by 0
Related Papers
Obesity and Cancer: A Current Overview of Epidemiology, Pathogenesis, Outcomes, and Management
|Cancers|2023|640
Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non–Small Cell Lung Cancer
|JAMA|2024|359
Gallbladder Cancer in the 21st Century
|Journal of Oncology|2015|301
The Genotype-Tissue Expression (GTEx) project
|Nature Genetics|2013|266
A decision framework for the analysis of green supply chain contracts: An evolutionary game approach
|Expert Systems with Applications|2011|246